Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8931357 | 0.81 | MTNR1A (0.42) | MTNR1ASMYD3NPC1MAPK13MAPK12 | |
| SCHEMBL30681543 | 0.81 | PNMT (0.56) | PNMTMAPTGAAAR | |
| SCHEMBL11746483 | 0.77 | ESR1 (0.36) | PNMTNPC1MAPTGAAKDM4E | |
| SCHEMBL24427517 | 0.77 | GAA (0.36) | GAAARALDH1A1 | |
| SCHEMBL23352926 | 0.76 | MTNR1A (0.45) | MTNR1ASMYD3NPC1MAPK13MAPK12 | |
| SCHEMBL11746431 | 0.76 | PNMT (0.49) | PNMTMAPTHTR2C | |
| SCHEMBL21505326 | 0.74 | PNMT (0.68) | PNMT | |
| SCHEMBL19774297 | 0.74 | MTNR1A (0.47) | MTNR1ASMYD3NPC1MAPK13MAPK12 | |
| SCHEMBL22262392 | 0.74 | MTNR1A (0.49) | PNMTMTNR1ASMYD3NPC1MAPK13 | |
| SCHEMBL22262394 | 0.74 | MTNR1A (0.49) | PNMTMTNR1ASMYD3NPC1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103709072-B | Optically active trifluoromethyl amine compound and preparation method thereof | CHINESE ACAD INST CHEMISTRY | 2015-06-24 | — | — | CN | disclosed |
| WO-2015040424-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AND THEIR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2015-03-26 | — | — | WO | disclosed |
| CN-103709072-A | Optically active trifluoromethyl amine compound and preparation method thereof | CHINESE ACAD INST CHEMISTRY | 2014-04-09 | — | — | CN | disclosed |
| CN-102850349-A | Fused, tricyclic sulfonamide inhibitors of gamma secretase | ELAN PHARM INC | 2013-01-02 | — | — | CN | disclosed |
| CN-101501032-B | fused tricyclic sulfonamides as gamma secretase inhibitors | ELAN PHARM INC | 2012-10-10 | — | — | CN | disclosed |
| EP-2450358-A1 | Fused, tricyclic sulfonamide inhibitors of gamma secretase | Elan Pharmaceuticals Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2450358-A1 | Fused, tricyclic sulfonamide inhibitors of gamma secretase | Elan Pharmaceuticals Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8153651-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-10 | — | — | US | disclosed |
| EP-2215054-B8 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2012-02-08 | — | — | EP | disclosed |
| EP-2215054-B1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS INC (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110021514-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2215054-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| CN-101501032-A | Fused tricyclic sulfonamides as gamma secretase inhibitors | ELAN PHARM INC (US) | 2009-08-05 | — | — | CN | disclosed |
| WO-2009064449-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007143523-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | PNMT 4597/4885MTNR1A 2992/4885SMYD3 2335/4885 |
| US-20110021514-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | PNMT 4063/4885MTNR1A 1153/4885SMYD3 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.